GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Operating Margin %

AVANIR Pharmaceuticals (FRA:AV2B) Operating Margin % : -38.77% (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. AVANIR Pharmaceuticals's Operating Income for the three months ended in Sep. 2014 was €-9.84 Mil. AVANIR Pharmaceuticals's Revenue for the three months ended in Sep. 2014 was €25.38 Mil. Therefore, AVANIR Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2014 was -38.77%.

Warning Sign:

AVANIR Pharmaceuticals operating margin has been in 5-year decline. The average rate of decline per year is -45.3%.

The historical rank and industry rank for AVANIR Pharmaceuticals's Operating Margin % or its related term are showing as below:

FRA:AV2B' s Operating Margin % Range Over the Past 10 Years
Min: -1373.1   Med: -329.33   Max: 35.08
Current: -40.29


FRA:AV2B's Operating Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 6.075 vs FRA:AV2B: -40.29

AVANIR Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was -45.30% per year.

AVANIR Pharmaceuticals's Operating Income for the three months ended in Sep. 2014 was €-9.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2014 was €-34.40 Mil.


AVANIR Pharmaceuticals Operating Margin % Historical Data

The historical data trend for AVANIR Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Operating Margin % Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -935.94 -577.60 -141.50 -94.77 -40.29

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -159.33 -37.38 -43.69 -41.54 -38.77

Competitive Comparison of AVANIR Pharmaceuticals's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Operating Margin % falls into.



AVANIR Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

AVANIR Pharmaceuticals's Operating Margin % for the fiscal year that ended in Sep. 2014 is calculated as

Operating Margin %=Operating Income (A: Sep. 2014 ) / Revenue (A: Sep. 2014 )
=-35.963 / 89.263
=-40.29 %

AVANIR Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2014 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2014 ) / Revenue (Q: Sep. 2014 )
=-9.84 / 25.379
=-38.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVANIR Pharmaceuticals  (FRA:AV2B) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


AVANIR Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines